Biomerica (BMRA) Current Deferred Revenue (2012 - 2026)

Biomerica has disclosed Current Deferred Revenue across 14 years of filings, most recently posting $30000.0 for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $30000.0, down 45.45% year-over-year; the trailing twelve-month figure through Feb 2026 was $30000.0 (down 45.45% YoY), and the FY2025 annual result was $55000.0, down 35.29% from the prior year.
• Current Deferred Revenue came in at $30000.0 for Q1 2026 at Biomerica, roughly flat from $30000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $3.2 million in Q1 2022 to a low of $30000.0 in Q4 2025.
• The 5-year median for Current Deferred Revenue is $60000.0 (2023), against an average of $255623.6.
• Across the five-year window, Current Deferred Revenue plunged 97.72% in 2022 and surged 41.67% in 2024, its largest moves.
• Biomerica's Current Deferred Revenue stood at $49013.0 in 2022, then increased by 22.42% to $60000.0 in 2023, then soared by 41.67% to $85000.0 in 2024, then plunged by 64.71% to $30000.0 in 2025, then changed by 0.0% to $30000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $30000.0 (Q1 2026), $30000.0 (Q4 2025), and $54000.0 (Q3 2025), per Business Quant data.